Veracyte Names Kevin Haas as Chief Development and Technology Officer
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company’s global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company’s end-to-end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316934398/en/Veracyte Names Kevin Haas as Chief Development and Technology OfficerAs Veracyte’s pipeline expands into whole-genome minimal residual disease (MRD) and other multi-omics applications, product development requires integrated capabilities across assays, software, AI, and next-generation i
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- Veracyte Names Kevin Haas as Chief Development and Technology Officer [Yahoo! Finance]Yahoo! Finance
- Veracyte (VCYT) was downgraded by Zacks Research from "strong-buy" to "hold".MarketBeat
- Veracyte (VCYT) had its "underweight" rating reaffirmed by Morgan Stanley.MarketBeat
- Veracyte (VCYT) Valuation Check After Strong 2025 Earnings And Reaffirmed 2026 Growth Outlook [Yahoo! Finance]Yahoo! Finance
- Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening [Yahoo! Finance]Yahoo! Finance
VCYT
Earnings
- 2/25/26 - Beat
VCYT
Sec Filings
- 3/16/26 - Form 8-K
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- VCYT's page on the SEC website